| scholarly article | Q13442814 |
| P2093 | author name string | Paul Martin | |
| Paul D Smith | |||
| Barry R Davies | |||
| Mark Cockerill | |||
| Armelle Logie | |||
| Jennifer S McKay | |||
| Richard Jenkins | |||
| Samantha Steele | |||
| Sue Cartlidge | |||
| P2860 | cites work | Mutations of the BRAF gene in human cancer | Q27860760 |
| P433 | issue | 8 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 2209-2219 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | |
| P478 | volume | 6 |
| Q40492036 | 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species |
| Q92761643 | A DSTYK mutation activates ERK1/2 signaling to promote intraspinal dissemination in a case of solitary fibrous tumor/hemangiopericytoma |
| Q27316326 | A MAPK-Driven Feedback Loop Suppresses Rac Activity to Promote RhoA-Driven Cancer Cell Invasion |
| Q33426534 | A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma |
| Q42673662 | A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens |
| Q82758717 | A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens |
| Q28475822 | A kernelisation approach for multiple d-Hitting Set and its application in optimal multi-drug therapeutic combinations |
| Q24651455 | A new fork for clinical application: targeting forkhead transcription factors in cancer |
| Q42363767 | A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors |
| Q33439877 | A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors |
| Q36677966 | A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer |
| Q35563528 | A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors |
| Q48220009 | Activating KRAS mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma. |
| Q33956177 | Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer |
| Q39352296 | Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. |
| Q37182194 | Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. |
| Q38091649 | Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring |
| Q53264472 | Advances in the preclinical testing of cancer therapeutic hypotheses |
| Q38148583 | Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. |
| Q38817910 | Allosteric modulators of MEK1: drug design and discovery |
| Q36544152 | Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. |
| Q42437883 | Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells |
| Q33820374 | Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models |
| Q37345775 | Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner |
| Q37410515 | Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263. |
| Q28749134 | Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim |
| Q37605160 | Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics |
| Q26750639 | Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies |
| Q37268123 | BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing |
| Q37772444 | BRAF, a target in melanoma: implications for solid tumor drug development |
| Q38945477 | BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer |
| Q42478581 | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells |
| Q37154615 | Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation |
| Q35939402 | Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression |
| Q41503593 | Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer |
| Q33732534 | Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. |
| Q36813976 | CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo |
| Q57468729 | Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens |
| Q35501246 | Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges |
| Q51437778 | Clarifying binding difference of ATP and ADP to extracellular signal-regulated kinase 2 by using molecular dynamics simulations |
| Q44004637 | Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma |
| Q36698868 | Collections of simultaneously altered genes as biomarkers of cancer cell drug response |
| Q41836780 | Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. |
| Q54314770 | Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. |
| Q33685977 | Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm |
| Q35836350 | Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis |
| Q47123785 | Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems |
| Q39142678 | Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. |
| Q28542683 | Comprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapy |
| Q39916105 | Converting cell lines representing hematological malignancies from glucocorticoid-resistant to glucocorticoid-sensitive: signaling pathway interactions |
| Q47145152 | Correlation between MEK signature and Ras gene alteration in advanced gastric cancer |
| Q41654291 | Cox-2-derived PGE2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma. |
| Q27022355 | Current and future trials of targeted therapies in cutaneous melanoma |
| Q42202805 | DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model. |
| Q28542760 | Data-derived modeling characterizes plasticity of MAPK signaling in melanoma |
| Q37803366 | Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). |
| Q27644273 | Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors |
| Q64263114 | Design, synthesis, and anticancer evaluation of novel quinoline derivatives of ursolic acid with hydrazide, oxadiazole, and thiadiazole moieties as potent MEK inhibitors |
| Q51572072 | Determination of selumetinib, N-desmethyl selumetinib and selumetinib amide in human biological samples by LC-MS/MS. |
| Q35677936 | Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy. |
| Q39134511 | Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy |
| Q26781362 | Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers |
| Q39140529 | Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors |
| Q50981985 | Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models |
| Q34644692 | Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma |
| Q37038401 | Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. |
| Q40457293 | ERK Signaling Is Essential for Macrophage Development. |
| Q41882870 | ERK1/2 signalling protects against apoptosis following endoplasmic reticulum stress but cannot provide long-term protection against BAX/BAK-independent cell death. |
| Q36507554 | Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma |
| Q39178760 | Effect of selumetinib on the growth of anastrozole-resistant tumors |
| Q35213763 | Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK |
| Q64075146 | Elucidating the transcriptional program of feline injection-site sarcoma using a cross-species mRNA-sequencing approach |
| Q37691441 | Emerging MEK inhibitors. |
| Q38172608 | Emerging protein kinase inhibitors for non-small cell lung cancer |
| Q37421296 | Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. |
| Q38973740 | Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. |
| Q35146186 | Enhancement of 5-Fluorouracil-induced In Vitro and In Vivo Radiosensitization with MEK Inhibition |
| Q35675442 | Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches. |
| Q41697013 | Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib |
| Q39623358 | Exploiting the origins of Ras mediated squamous cell carcinoma to develop novel therapeutic interventions |
| Q33767083 | FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells |
| Q33698374 | From basic research to clinical development of MEK1/2 inhibitors for cancer therapy |
| Q37999967 | From genes to drugs: targeted strategies for melanoma |
| Q47356048 | Generation of stable PDX derived cell lines using conditional reprogramming |
| Q36563659 | Genetics of melanoma |
| Q43189894 | Genome-wide identification of chemosensitive single nucleotide polymorphism markers in colorectal cancers |
| Q36628641 | Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes |
| Q36618983 | Grifolin directly targets ERK1/2 to epigenetically suppress cancer cell metastasis |
| Q37632192 | HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma |
| Q92084382 | Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists |
| Q33717222 | High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886) |
| Q37635287 | High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. |
| Q55079595 | Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation. |
| Q64921561 | Hyaluronic Acid Layered Chimeric Nanoparticles: Targeting MAPK-PI3K Signaling Hub in Colon Cancer Cells. |
| Q41782221 | Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome. |
| Q34129528 | Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines |
| Q37596249 | Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. |
| Q49787333 | Implications of KRAS mutations in acquired resistance to treatment in NSCLC. |
| Q33557673 | In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase |
| Q38402255 | Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells |
| Q35944601 | Inhibition of Ras for Cancer Treatment: The Search Continues |
| Q39396267 | Inhibition of metadherin sensitizes breast cancer cells to AZD6244 |
| Q41345175 | Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer |
| Q34415484 | Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. |
| Q34273541 | Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells |
| Q34544971 | KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer |
| Q38390027 | KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach |
| Q42062700 | KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition |
| Q49887897 | KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target |
| Q38669282 | KRAS-Mutant Lung Cancers in the Era of Targeted Therapy |
| Q39860040 | KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer |
| Q38254501 | MEK inhibition in non-small cell lung cancer |
| Q92531455 | MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells |
| Q38092584 | MEK inhibitors as a chemotherapeutic intervention in multiple myeloma |
| Q56889985 | MEK inhibitors for the treatment of NRAS mutant melanoma |
| Q47318847 | MEK inhibitors under development for treatment of non-small-cell lung cancer |
| Q27777362 | MEK1 mutations confer resistance to MEK and B-RAF inhibition |
| Q36328021 | MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms |
| Q36976683 | MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands |
| Q37179748 | MEK1/2 inhibition suppresses tamoxifen toxicity on CNS glial progenitor cells. |
| Q35872321 | MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model |
| Q38179145 | MEK1/2 inhibitors in the treatment of gynecologic malignancies. |
| Q89303329 | Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine |
| Q38007869 | Mechanisms of acquired resistance to ERK1/2 pathway inhibitors |
| Q91891857 | Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer |
| Q26738377 | Metastatic disease from uveal melanoma: treatment options and future prospects |
| Q28468669 | Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells |
| Q36979035 | Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. |
| Q30433431 | Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC) |
| Q34052520 | Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia |
| Q42330675 | NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer |
| Q37888981 | New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances |
| Q37345841 | New treatment options for advanced pancreatic cancer |
| Q34671658 | Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy |
| Q38799963 | Novel investigational therapies for treating biliary tract carcinoma |
| Q37828536 | Novel mitogen-activated protein kinase kinase inhibitors |
| Q34774990 | Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17 |
| Q50061136 | Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling. |
| Q35896845 | Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. |
| Q44502910 | Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. |
| Q51650705 | Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies |
| Q100490609 | Overview of current targeted therapy in gallbladder cancer |
| Q35096292 | Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice |
| Q54982668 | Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor. |
| Q27851426 | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers |
| Q35023451 | Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma |
| Q37505185 | Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements |
| Q27853084 | Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. |
| Q27852623 | Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. |
| Q34633455 | Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma |
| Q38757884 | Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. |
| Q33729778 | Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas |
| Q37421431 | Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. |
| Q38256348 | Profile of selumetinib and its potential in the treatment of melanoma |
| Q34749852 | Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer |
| Q50938980 | Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis. |
| Q38132900 | Protein kinase inhibitors in melanoma |
| Q34580110 | Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition |
| Q38227885 | Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting |
| Q34307356 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance |
| Q35679353 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health |
| Q39140763 | Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer |
| Q42613657 | Regulation of autophagy by ceramide-CD95-PERK signaling |
| Q35971560 | Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer |
| Q54109659 | Research Progress of KRAS Mutation in Non-small Cell Lung Cancer |
| Q34417585 | Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. |
| Q38723005 | Role of key genetic mutations on increasing migration of brain cancer cells through confinement. |
| Q47432675 | SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer |
| Q35035656 | SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors |
| Q54310457 | Selumetinib for the treatment of cancer |
| Q38798084 | Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives |
| Q38663069 | Selumetinib for the treatment of non-small cell lung cancer |
| Q38836927 | Selumetinib in the treatment of non-small-cell lung cancer |
| Q34652628 | Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study |
| Q27851971 | Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study |
| Q39466460 | Selumetinib: A Promising Pharmacologic Approach for KRAS -Mutant Advanced Non-Small-Cell Lung Cancer |
| Q36560775 | Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status |
| Q38747573 | Signaling pathways as therapeutic targets in biliary tract cancer. |
| Q38090664 | Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition |
| Q34104350 | Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells |
| Q37268127 | Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms |
| Q39725762 | Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. |
| Q38585847 | Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. |
| Q30384829 | Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). |
| Q35691935 | Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells |
| Q39206681 | Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells |
| Q38702245 | Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. |
| Q35018805 | Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models |
| Q92862513 | Synthesis and biological evaluation of novel N-(piperazin-1-yl)alkyl-1H-dibenzo[a,c]carbazole derivatives of dehydroabietic acid as potential MEK inhibitors |
| Q35584299 | Systematic review of medical treatment in melanoma: current status and future prospects. |
| Q36233325 | Targeted Therapy for MAPK Alterations in Pediatric Gliomas |
| Q38127728 | Targeted therapy for NSCLC with driver mutations |
| Q54783170 | Targeting RAS and PI3K in lung cancer. |
| Q38272894 | Targeting RAS-ERK signalling in cancer: promises and challenges |
| Q38124821 | Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma |
| Q37629722 | Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors |
| Q38554422 | Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances |
| Q38388217 | Targeting of MEK in lung cancer therapeutics |
| Q36068326 | Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. |
| Q38799845 | Targeting the KRAS Pathway in Non-Small Cell Lung Cancer |
| Q38682370 | Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications |
| Q37745182 | Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail |
| Q36278239 | Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy |
| Q39270291 | Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma |
| Q27853330 | Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma |
| Q38104439 | That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. |
| Q38621231 | The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment |
| Q35835097 | The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models |
| Q38397326 | The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. |
| Q38788201 | The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition. |
| Q38212717 | The clinical development of MEK inhibitors |
| Q35140947 | The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma |
| Q35793641 | The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. |
| Q39380338 | The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition |
| Q37951743 | Towards new therapeutic approaches for malignant melanoma |
| Q38300326 | Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244) |
| Q38787635 | Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. |
| Q37133208 | Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel |
| Q39301436 | Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance |
| Q37290943 | Tumour cell survival signalling by the ERK1/2 pathway |
| Q37034487 | Understanding signaling cascades in melanoma |
| Q34438500 | Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R |
| Q39680200 | Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway |
| Q37172903 | Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation |
| Q36922674 | Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation |
| Q44561867 | Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets |
Search more.